News Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
4.83 ^USD	+2.33%		+4.32%	-1.23%

Jul. 01	Capricor Therapeutics Joins Russell 3000, Russell 2000 Indexes	MT
Jul. 01	Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 3000E Growth Index	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes	Jul. 02	AQ
Capricor Therapeutics Joins Russell 3000, Russell 2000 Indexes	Jul. 01	MT
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes	Jul. 01	AQ
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 3000E Growth Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 2000 Growth Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 2000 Dynamic Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 2500 Growth Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 2500 Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 3000 Index	Jun. 30	CI
Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 3000E Value Index	Jun. 30	CI
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy	Jun. 28	AQ
Capricor Therapeutics, Inc. Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy	Jun. 28	CI
Capricor Therapeutics	Jun. 26	AQ
Capricor Therapeutics	Jun. 25	AQ
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy	Jun. 25	AQ
Capricor Therapeutics, Inc. Announces for the Treatment of Duchenne Muscular Dystrophy	Jun. 25	CI
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Jun. 11	MT
Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise	Jun. 11	MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway	Jun. 11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Summary

Filters